Biodexa Pharmaceuticals
CARDIFF, X0, United Kingdom · Biopharma, Biotechnology, Healthcare · 22 employees
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of t
Funding history
- Funding Round — $5.0M — Aug 2024
- Funding Round — $6.8M — Jan 2024
- Series seed — $3.3M — Jun 2023
- Funding Round — $6.0M — Feb 2023
- Series seed — $3.0M — Jun 2020
Recent signals
- Jan 05, 2026: Biodexa Pharmaceuticals Appoints Fiona Sharp as Chief Financial Officer
- Aug 01, 2024: Raised $5.0M
- Jan 04, 2024: Raised $6.8M
- Jun 07, 2023: Raised $3.3M in Series seed
- Feb 17, 2023: Raised $6.0M
- Jun 04, 2020: Raised $3.0M in Series seed
- Nov 07, 2019: Raised $3.0M in Series seed
See plans & pricing → Track Biodexa Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.